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Vancomycin is one of the older antibiotics that has been now in clinical use close to 60 years.
Earlier on, vancomycin was associated with many side effects including vestibular and renal,
most likely due to impurities contained in early vancomycin lots. Over the years, the impuri-
ties have been removed and the compound has now far less vestibular adverse effects, but
still possesses renal toxicity if administered at higher doses rendering trough serum levels
of >15 mcg/mL or if administered for prolonged periods of time. Vancomycin is effective
against most Gram-positive cocci and bacilli with the exception of rare organisms as well as
enterococci that became vancomycin resistant, mostly Enterococcus faecium. The major
use of vancomycin today is for infections caused by methicillin-resistant Staphylococcus
aureus (MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE) and amoxicillin-
resistant enterococci. In its oral form, vancomycin is used to treat diarrhea caused by
Clsotridium difficile.With S. aureus, there are only a handful of vancomycin-resistant strains.
Nevertheless, a “vancomycin creep” that is slow upward trending of vancomycin MIC from
<1 mcg/mL to higher values has been noted in several parts of the world, but not globally,
and strains that have MIC’s of 1.5–2 mcg/mL are associated with high therapeutic fail-
ure rates.This phenomenon has also been recently recognized in methicillin-susceptible S.
aureus (MSSA).While vancomycin is relatively a safe agent adverse events include the “red
man” syndrome, allergic reactions, and various bone marrow effects as well as nephrotox-
icity. Vancomycin has been a very important tool in our therapeutic armamentarium that
remained effective for many years, it is likely remain effective as long as resistance to
vancomycin remains controlled.
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Vancomycin was isolated in 1957 by Dr. E.C Kornfield, an organic
chemist with Eli Lilly in the deep jungles in Borneo from a fun-
gus named Streptomyces orientalis. Soil samples from that jungle
of where the fungus was isolated yielded in broth fermentation
a compound that was highly effective and bactericidal against
Staphylococci. The initial compound was labeled 05865 and initial
studies have shown that Staphylococci failed to develop resis-
tance to 05865 following serial passages in media containing
this agent. As in this period, there was a growing problem of
drug-resistant Staphylococci, the FDA granted 05865 a “fast track
approval,” on the basis of open – labeled studies submitted to the
agency in 1958. 05865 was subsequently labeled as “vancomycin,”
a term derived from the word vanquish. The original product-
vancomycin, obtained by fermentation, contained considerable
amounts (up to 70%) of impurities, and had a brown color earning
it the nickname “Mississippi Mud” (1, 2).
Vancomycin is active against Gram-positive aerobic cocci and
bacilli, e.g., Staphylococci, Streptococci, Enterococci, and Pneumo-
cocci as well as Corynebacterium, Listeria, Bacillus spp, Clostridia,
and oral Gram-positive anaerobes. Vancomycin is active against
methicillin-resistant Staphylococcus aureus (MRSA) and against
methicillin-resistant Staphylococcus epidermidis (MRSE), as well as
against penicillin-resistant Corynebacterium jeikeium, Streptococ-
cus pneumoniae, and Clostridium difficile. Strains of Leuconosoc,
Lactobacillus, Pediococcus, and Erysipelothrix possess inherent
resistance to vancomycin.
Vancomycin remains the first-line agent for methicillin-
resistant coagulase-negative and coagulase-positive staphylococ-
cal infections, including bacteremia, endocarditis, pneumonia,
cellulitis, and osteomyelitis. In addition, it is used to treat seri-
ous Gram-positive infections among patients who are allergic to
semi-synthetic penicillins or cephalosporins (3).
While vancomycin is bactericidal against all susceptible Gram-
positive pathogens it exerts only bacteriostatic activity against
enterococci and needs to be combined with another agent, usually
an aminoglycoside, to achieve bactericidal activity. In addition,
vancomycin possesses activity against Gram-positive anaerobes
including Clostridium species as well as oral anaerobes such as
peptostreptococcus, propiobacterium, etc. (including C. difficile),
but is lacking activity against Gram-negative bacilli. Vancomycin
“slow bactericidal” activity against MSSA, compared to β-lactams,
this slow activity is reflected also in the worse clinical out-
comes of cases of MSSA bacteremia and pneumonia treated with
vancomycin (4–7).
Vancomycin is a tricyclic glycopeptide (Figure 1) that consists
of seven membered peptide chains forming the tricyclic structure
and attached disaccharide composed of vancosamine and glucose.
The molecular weight is 1485 and thus vancomycin is heavier
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FIGURE 1 |Vancomycin structure.
that most β-lactam antibiotics, but similar in weight to the unre-
lated compound daptomycin. It has similar molecular weight to
teicoplanin and its derivative dalbavancin, to the semi-synthetic
telavancin, as well as the more distantly related semi-synthetic
lipoglycopeptide oritavancin (8).
Vancomycin and the above mentioned compounds inhibit cell
wall synthesis in its later stages thus affecting dividing bacteria.
The target of their activity is the murein monomers, which are
peptidoglycan precursors. The murein monomers are added to the
peptidoglycan by transglycosylation followed by transpeptidation.
Vancomycin binds to the d-ala-d-ala moiety of the monomers,
subsequently the monomers cross the cell membrane. This com-
plex leads to conformational change that blocks the glycosyltrans-
ferase leading to inhibition of the incorporation of the murein
monomers to the growing peptidoglycan chain and preventing
further transpeptidation with consequent interruption of the cell
wall synthesis.
When methicillin and subsequently other anti-staphylococcal
penicillins (cloxacillin, dicloxacillin, flucloxacillin, etc.) were intro-
duced to the market, the clinical utility of vancomycin was dis-
placed from its position as first-line anti-staphylococcal therapy
to second-line anti-staphylococcal therapy, mainly because of its
nephrotoxicity and ototoxicity observed in the early clinical trials
(1). It is clear today, that earlier observations of nephrotoxicity and
ototoxicity were largely due to the impurities of the earlier prepa-
rations. The additional compounds accounted to up to 70% of
vancomycin contained in the injection vials. Later, in the 1970s
when newer preparations of vancomycin were introduced, the
issue of ototoxicity has essentially disappeared and nephrotoxicity
was diminished considerably unless vancomycin was used in com-
bination with aminoglycosides; the same was also seen in animal
experiments (9, 10).
Vancomycin is in broad clinical use with the main indica-
tions including skin and soft tissue infections and osteomyelitis.
It is used for these indications empirically, prior to availability of
culture results, and when MRSA is the culprit. Similarly, it is fre-
quently used for treatment of bacteremia and endocarditis where
MRSA is deemed a possible cause. In this context, once MSSA is
documented as the causative agent, vancomycin has been associ-
ated with inferior outcomes and should therefore not be used for
MSSA bacteremia or endocarditis (4–7). In addition, vancomycin
is used to treat gram-positive pneumonia, primarily in context
of hospital-acquired infections and in the treatment of bacterial
meningitis caused by penicillin-resistant Streptococcus pneumonia.
The worldwide emergence of methicillin-resistant Staphylococci
(MRSA and MRSE) in the 1970s, brought vancomycin back to
the stage. At this juncture, pharmacokinetics became popular and
blood concentrations were determined, and the first normograms
with dosage adjustments for patients with renal impairment were
published (11).
The subsequent emergence of vancomycin resistance among
enterococci in the mid-1980s and failure of such patients even if
they had enterococci with vancomycin-intermediate susceptibil-
ity was described, resulting in vancomycin losing it omnipotence
for all gram-positive cocci (12). The appearance of S. aureus
strains with intermediate susceptibility to vancomycin (VISA) and
vancomycin-resistant S. aureus (VRSA) (12–14) and vancomycin-
resistant S. epidermidis (VRSE) (15, 16), brought an end to the
hitherto hegemony of vancomycin in the Gram-positive coc-
cal arena. Fortunately, the occurrence of these difficult to treat
Staphylococci remains rare.
Normally, the suggested minimal inhibitory concentration
(MIC) of vancomycin against S. aureus was ≤2 mcg/mL. It has
been repeatedly shown that clinical failures in patients with endo-
carditis, bacteremia, and pneumonia occur when the S. aureus
strains causing these infections have MIC of ≥2 mcg/mL (17–19).
Even within the range of MICs below 2 mcg/mL, a high failure
rate was also observed in patients infected with strains that has
vancomycin MIC of 1.5 (20, 21).
A phenomenon named “vancomycin Creep” was described in
recent years denoting a slow but steady increase in vancomycin
MIC observed over time, from values of 0.5–0.75 mcg/mL to levels
of 1.25–1.5 mcg/mL (22, 23). In some parts of the world, however,
this phenomenon of “vancomycin creep” does not occur (24).
Therapeutic monitoring of vancomycin levels in adults: for
many years a disagreement existed regarding the need for mea-
surement of vancomycin levels. The discussion was justified as
long as most vancomycin MIC were ≤1 mcg/mL, this situation
has, however, changed and with increasing MIC’s a decreased clin-
ical success became evident (25, 26). In patients infected with
strains that had MIC of 4 mcg/mL and above the failure rate
of vancomycin reached 60%, this has led many bodies (FDA,
ICLS) to reduce in 2008 the limit of susceptibility (breakpoint)
to 2 mcg/mL. The other reason for measuring serum concentra-
tions is to avoid toxicity, which becomes apparent when serum
trough levels exceed 15 mcg/mL (27–29).
Vancomycin resistance among enterococci is attributed to
change in the d-alanyl-d-alanine portion of peptide precursor
units, transmitted as Van genes, thus rendering it incapable of
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inhibiting peptidoglycan polymerase and transpeptidation reac-
tions. While the mechanisms that lead to vancomycin resistance
are clear, the reasons behind the emergence of these strains are
attributed to a myriad of causes (30–32). Thus far, at least eight
types of acquired resistance to glycopeptides have been reported
on the basis of phenotypic and genotypic criteria (VanA, VanB,
VanD, VanE, VanG, VanL, VanM, VanN, and VanC). VanC being
constitutively expressed by Enterococcus gallinarum and Enterococ-
cus casseliflavus (33, 34). Carriage of VRE in the gastrointestinal
tract occurs more commonly after prolonged hospital admissions
and more frequently in high-risk units, such as intensive care units
(ICUs), hemato-oncology, and abdominal surgery wards. VRE col-
onization may persist for years, and a recent study from Korea
identified vancomycin exposure after colonization as the strongest
predictor of prolonged colonization, with odds ratio of 4.05 in
a multivariate model adjusting for potential confounders (35). It
has been speculated that exposure to oral vancomycin is an impor-
tant contributor to propagation of VRE in the healthcare setting,
as it drives prolonged colonization with VRE from a myriad of
sources (36, 37).
The challenge posed by MRSA with increasing vancomycin
MIC’s has led to attempts to treat such patients with higher doses
of vancomycin aiming to attain a trough level of >15 mcg/mL,
generally these attempts have not been associated with increased
success rate, but rather with increased nephrotoxicity (38, 39).
These doses are used in the context of S. aureus infections.
The effect of vancomycin antibacterial activity is pharmacoki-
netically dependent on the time that the serum concentration of
vancomycin is above the MIC. In vitro and the neutropenic mouse
thigh infection models have demonstrated that the area under the
concentration curve (AUC) divided by the MIC (AUC/MIC) is the
best predictor of the activity of vancomycin against methicillin-
susceptible S. aureus (MRSA), and glycopeptide-intermediate S.
aureus (GISA) (40). However, in a Streptococcus pneumoniae non-
neutropenic mouse peritonitis model, Knudsen et al. (41) demon-
strated that the peak serum concentration divided by the MIC
(peak/MIC) was the pharmacodynamic parameter with the most
predictive value. In patients with MRSA pneumonia an AUC/MIC
value of ≥400 was associated with a successful outcome, whereas
an AUC/MIC value of ≤400 was associated with a lower eradica-
tion rate and a higher mortality rate (P = 0.005) (42) With strains
that have a MIC of ≥2 mcg/mL this desired AUC/MIC ratio of
400 is more difficult to achieve and attainment of lower AUC/MIC
ratios has been associated with poorer outcomes in the context of
bacteremia (43, 44).
Vancomycin is not appreciably absorbed orally, and is elim-
inated primarily via the renal route, with >80–90% recovered
unchanged in the urine within 24 h after administration of a
single dose. The pharmacokinetic profile of vancomycin can be
characterized by either a 2- or 3-compartment pharmacokinetic
profile (45).
Vancomycin is normally administered intravenously, with a
standard infusion time of at least 1 h′, to minimize infusion-related
adverse effects. In patients with normal creatinine clearances, van-
comycin has a α-distribution phase of ~30 min to 1 h′ and a
β-elimination half-life of 6–12 h. The volume of distribution is
0.4–1 L/kg. The binding of vancomycin to protein ranges from
10 to 50%. Factors that affect the overall activity of vancomycin
include its tissue distribution, inoculum size, and protein-binding
effects (45–48).
Oral vancomycin is not absorbed systemically and achieves high
levels in the colon thus oral vancomycin formulation may be used
at a dose of 125 mg q6h, and less frequently a higher dose of 500 mg
four times daily is equally effective (against C. difficile colitis). Oral
vancomycin is indicated for patients with either severe C. difficile
colitis (high leukocyte count >15,000, serum creatinine increase
≥50% from baseline), or those with C. difficile colitis that failed
other therapeutic modalities (mainly metronidazole) (49). Intra-
venous vancomycin on the other hand, has no effect on C. difficile
colitis since it is not excreted appreciably into the gastrointestinal
tract. Intracolonic vancomycin administration at the same dose
and frequency may be considered in patients with profound ileus.
In patients with ileostomy, the same dose is administered as well.
Vancomycin-associated nephrotoxicity can still be seen, even in
the presence of appropriate serum concentrations, especially when
it is co-administered with aminoglycosides, amphotericin B, fos-
carnet, pentamidine ACE inhibitors, loop diuretics, cyclosporine,
cyclophosphamide, and the platinums but also when vancomycin
therapy exceeds 14 days and in patients with very high APACHE
scores (50).
The most common adverse events that are not related to van-
comycin serum levels are: fever, chills, and phlebitis. The “red
man” (Figure 2) syndrome (RMS) is manifested by: tingling and
red flushing of the face, upper torso, and upper extremities. It is
thought to be mediated by histamine release from mast cells, it
is considered as pseudo-allergic drug reaction without underlying
immunological processes (51). The phenomena is enhanced by co-
administration of opiates (52) and can be diminished or aborted
by slowing the infusion rate of vancomycin to ≤10 mg/min, and
premedication with diphenhydramine (50 mg orally or intra-
venously) as well as ranitidine (50 mg orally or intravenously) (53).
Should higher doses of vancomycin be administered (>1 g′) the
infusion time needs to be prolonged if the RMS occurs.
Neutropenia is observed not infrequently in patients receiv-
ing vancomycin for longer periods of time. The exact incidence
is difficult to ascertain due to co-administration of other poten-
tially marrow suppressive medications and due to the underly-
ing sepsis or diseases. This adverse event is not related to van-
comycin serum concentrations, and is reversible when the agent is
discontinued (54).
FIGURE 2 | “Red man” syndrome.
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Thrombocytopenia (immune), as well as leukocytosis,
eosinophilia, and leukocytoclastic vasculitis have been associated
with vancomycin (55, 56). Drug fever is considered infrequent and
occasionally appears along with neutropenia (57).
Anaphylactic reaction is mediated by drug-specific IgE anti-
bodies. Patients with anaphylactic reactions to vancomycin often
have a history of multiple prior exposures, the reaction is
considered rare, although angioedema, respiratory distress, and
bronchospasm, with demonstrable drug-specific IgE have been
described (58).
A cross allergic reaction between vancomycin and other gly-
copeptides has been described for teicoplanin but not for other
glycopeptides (59).
Other dermatological manifestation of vancomycin are: DRESS
(drug rash with eosinophilia and systemic symptoms) also named
DiHS (drug-induced hypersensitivity syndrome). This is a sys-
temic response, in which rash, mucosal involvement, atypi-
cal lymphocytes, frequent eosinophilia, and lymphadenopathy
occur together with organ involvement (kidneys, liver, myocardi-
tis/pericarditis). Treatment includes discontinuation of drug ther-
apy and avoiding its use in the future and glucocorticoids for a
short duration (60–62).
Vancomycin-related linear IgA bullous dermatosis (LABD)
is a rare, autoantibody-mediated skin reaction. LABD may be
confused with toxic epidermal necrolysis. The blistering bullous
lesions of LABD need to be differentiated from pemphigoid, ery-
thema multiforme, and dermatitis herpetiformis. Direct immuno-
fluorescence is usually needed to confirm the diagnosis of LABD.
Linear IgA deposition at the dermal–epidermal junction of the
basement membrane zone is the characteristic finding of LABD.
LABD can appear suddenly, appears to be idiosyncratic and unre-
lated to serum vancomycin levels (63, 64). Vancomycin is the most
common cause of drug-induced LABD (65).
Other severe cutaneous syndromes including Stevens–Johnson
syndrome,exfoliative dermatitis, toxic epidermal necrolysis, exten-
sive fixed drug eruption, and leukocytoclastic vasculitis have all
been described in association with vancomycin use (66, 67).
Desensitization procedure may be indicated for suspected IgE-
mediated reactions and for severe RMS that is refractory to
other measures and is less common with availability of appropri-
ate alternatives (such as linezolid, daptomycin, telavancin, quin-
upristin/dalfoprisin, tigecycline, and ceftaroline-all active against
MRSA). Desensitization is contraindicated in patients with the
DRESS syndrome and in those with exfoliative skin reactions
such as Stevens–Johnson syndrome and toxic epidermal necrol-
ysis. Desensitization for IgE-mediated allergy is usually per-
formed in an intensive care unit. Desensitization should be
performed immediately before the required treatment, because
maintaining tolerance requires continual exposure to the drug.
A rapid desensitization protocol (after up to date) is shown in
Table 1.
Mild symptoms may occur in 20–30% during desensitiza-
tion and are usually self-limited (e.g., flushing, pruritus, limited
urticaria), and can be managed without discontinuation of the
desensitization protocol (68). Mild symptoms are managed inter-
ruption of infusion and treating the symptoms that do not subside
Table 1 | Rapid vancomycin desensitization protocole (after up to
date).
Premedication:
Diphenhydramine 50 mg IV and hydrocortisone 100 mg IV 15 min prior to
initiation of protocol, then every 6 h throughout protocol
Infusion no. Dilution Vancomycin
dose (mg)
Concentration
(mg/mL)
1 1:10,000 0.02 0.0002
2 1:1000 0.2 0.002
3 1:100 2 0.02
4 1:10 20 0.2
5 Standard 500 2
Preparation
1. Prepare a standard bag of 500 mg vancomycin in 250 mL NS or D5W;
label as infusion number 5, vancomycin 2 mg/mL.
2. Draw up 10 mL of the standard vancomycin 2 mg/mL preparation and
place in 100 mL bag of NS or D5W; label as infusion number 4, vancomycin
0.2 mg/mL.
3. Draw up 10 mL of the 0.2-mg/mL solution and place in a 100-mL bag
of NS or D5W; label as infusion number 3, vancomycin 0.02 mg/mL.
4. Draw up 10 mL of the 0.02-mg/mL solution and place in a 100-mL bag
of NS or D5W; label as infusion number 2, vancomycin 0.002 mg/mL.
5. Draw up 10 mL of the 0.002-mg/mL solution and place in a 100-mL bag
of NS or D5W; label as infusion number 1, vancomycin 0.0002 mg/mL.
Infusion rate directions
Initiate infusion rate at 0.5 mL/min (30 mL/h) and increase by 0.5 mL/min
(30 mL/h) as tolerated every 5 min to a maximum rate of 5 mL/min
(300 mL/h). If pruritus, hypotension, rash, or difficulty breathing occurs,
stop infusion and reinfuse the previously tolerated infusion at the highest
tolerated rate. This step may be repeated up to three times for any given
concentration.
Upon completion of infusion number 5, immediately administer the
required dose of vancomycin in the usual dilution of NS or D5W over 2 h.
Decrease rate if patient becomes symptomatic or, alternatively, increase
rate if patient tolerated dose. Administer diphenhydramine 50 mg orally
60 min prior to each dose.
spontaneously. Once symptoms have subsided, the last tolerated
step is repeated. If moderate or severe symptoms develop, the
infusion should be discontinued and the symptoms treated. If
vancomycin is discontinued, even for a short while, desensitiza-
tion needs to be repeated in the previously described manner as the
chances for anaphylaxis following the re-start of the vancomycin
therapy are considerable (69).
Vancomycin has been a valuable agent for the management
of infections caused by gram-positive bacteria for many decades.
Attempts produce related derivatives as well as related compounds
with similar or better antimicrobial spectrum, particularly against
vancomycin-resistant enterococci and strains of VISA and MRSA
with increased vancomycin MIC’s are ongoing with notable exam-
ples including telavancin, dalbavancin, and oritavancin, the latter
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two poses longer half-lives and can be administered once-weekly.
In addition distinct classes with similar spectrum of activity such
as daptomycin and the streptogramin quinupristin/dalfopristin
may be used.
In clinical trials, these compounds were compared to van-
comycin and have been shown to be non-inferior (38, 70–76).
This leads us to believe that vancomycin will continue to be used
as the major glycopeptide antibiotic against MRSA and enterococci
that are vancomycin susceptible, as long as agents with superior
performance are not available.
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